PANoptosis: a novel therapeutic target and mechanistic insight into traditional Chinese medicine intervention in inflammatory bowel disease: a review
- 1Liaoning University of Traditional Chinese Medicine
- 2Department of Hemorrhoids and Fistula I, The Third Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
- 3Department of Proctology, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Abstract
The rising incidence of inflammatory bowel disease (IBD) and the limited efficacy of current therapies underscore the need for novel strategies. PANoptosis is an inflammatory programmed cell-death process integrating molecular features of pyroptosis, apoptosis, and necroptosis. Emerging evidence suggests that PANoptosis-related genes and signaling nodes may contribute to intestinal epithelial injury, mucosal immune activation, barrier disruption, and inflammatory amplification in inflammatory bowel disease. Traditional Chinese medicine and its active constituents have been reported to regulate inflammation, intestinal barrier integrity, gut microbiota, and several cell-death pathways. However, direct evidence that these agents inhibit bona fide PANoptosis in intestinal models remains limited. Current mechanistic evidence is strongest for selected compounds, such as baicalin, which has been shown in macrophages to interfere with mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly, whereas other proposed mechanisms are largely extrapolated from extra-intestinal models or from studies of apoptosis, pyroptosis, necroptosis, and inflammatory signaling. This narrative review summarizes the molecular basis of PANoptosis in IBD and critically evaluates the potential of traditional Chinese medicine-derived compounds and formulas to modulate upstream sensors, adaptor proteins, and downstream effectors of PANoptosis-related pathways. We emphasize that future studies should verify these mechanisms in intestinal epithelial cells, intestinal organoids, DSS/TNBS/IL-10-deficient colitis models, and human IBD tissues.
Related
- Target Discovery and Drug Intervention in Inflammatory Diseases： A Paradigm Shift from Mechanistic Dissection to Precision Therapy
- Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline
- PANoptosis-based HNSCPAN-index predicts prognosis and reveals DSCAM as a therapeutic target in head and neck squamous cell carcinoma
- Unlocking the therapeutic potential of traditional Chinese medicine in Crohn’s disease: from multi-target mechanisms to clinical promise
- Protocol for a cohort study of comprehensive intervention of psoriasis and diabetes comorbidity prevention and control using traditional Chinese medicine of blood-activating and stasis-dissolving method
BibTeX
@article{li2026panoptosis,
title = {{PANoptosis: a novel therapeutic target and mechanistic insight into traditional Chinese medicine intervention in inflammatory bowel disease: a review}},
author = {Xiaojian Li and Wei Guan and Yongduo Yu and Xinyao Xu and Shujian An},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1880406},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1880406/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - PANoptosis: a novel therapeutic target and mechanistic insight into traditional Chinese medicine intervention in inflammatory bowel disease: a review
AU - Xiaojian Li
AU - Wei Guan
AU - Yongduo Yu
AU - Xinyao Xu
AU - Shujian An
PY - 2026
DA - 2026/10/13
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1880406
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1880406/full
AB - The rising incidence of inflammatory bowel disease (IBD) and the limited efficacy of current therapies underscore the need for novel strategies. PANoptosis is an inflammatory programmed cell-death process integrating molecular features of pyroptosis, apoptosis, and necroptosis. Emerging evidence suggests that PANoptosis-related genes and signaling nodes may contribute to intestinal epithelial injury, mucosal immune activation, barrier disruption, and inflammatory amplification in inflammatory bowel disease. Traditional Chinese medicine and its active constituents have been reported to regulate inflammation, intestinal barrier integrity, gut microbiota, and several cell-death pathways. However, direct evidence that these agents inhibit bona fide PANoptosis in intestinal models remains limited. Current mechanistic evidence is strongest for selected compounds, such as baicalin, which has been shown in macrophages to interfere with mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly, whereas other proposed mechanisms are largely extrapolated from extra-intestinal models or from studies of apoptosis, pyroptosis, necroptosis, and inflammatory signaling. This narrative review summarizes the molecular basis of PANoptosis in IBD and critically evaluates the potential of traditional Chinese medicine-derived compounds and formulas to modulate upstream sensors, adaptor proteins, and downstream effectors of PANoptosis-related pathways. We emphasize that future studies should verify these mechanisms in intestinal epithelial cells, intestinal organoids, DSS/TNBS/IL-10-deficient colitis models, and human IBD tissues.
SN - 1663-9812
ER -